| GENERAL AND GOING CONCERN |
NOTE
1: GENERAL AND GOING CONCERN
| |
a. |
BriaCell
Therapeutics Corp. (“BriaCell” or the “Company”) was incorporated under the Business Corporations Act
(British Columbia) on July 26, 2006 and is listed on the Toronto Stock Exchange (“TSX”) under the symbol
“BCT”. The Company also trades on the Nasdaq Capital Market (“NASDAQ”) under the symbols “BCTX”,
“BCTXW” and “BCTXZ. |
| |
|
|
| |
b. |
BriaCell
is an immuno-oncology biotechnology company. The Company is currently advancing its Bria-IMT targeted immunotherapy program against
end-stage breast cancer to Phase 3 study which has been approved by the FDA. BriaCell is also developing a personalized off-the-shelf
immunotherapy, Bria-OTS™, and a soluble CD80 protein therapeutic which acts both as a stimulator of the immune system as well
as an immune checkpoint inhibitor. |
| |
|
|
| |
c. |
Going
concern |
The
Company continues to devote substantially all of its efforts toward research and development activities. In the course of such activities,
the Company has sustained operating losses and expects such losses to continue in the foreseeable future. The Company’s accumulated
deficit as of July 31, 2025 was $111,755,564
(July 31, 2024 - $85,443,697)
and negative cash flows from operating activities during the year ended July 31, 2025 was $28,170,520
(July 31, 2024 - $24,126,128).
The Company is planning to finance its operations by exploring additional sources of capital and financing, while managing its existing
working capital resources. During the year ended July 31, 2025, the Company raised $50.9 million in gross proceeds from equity financings,
however, the Company’s ability to continue as a going concern is dependent upon its ability to attain future profitable operations
and to continue to obtain the necessary financing to meet its obligations arising from normal business operations when they come
due. The uncertainty of the Company’s ability to raise such financial capital casts substantial doubt on the Company’s ability
to continue as a going concern. These consolidated financial statements do not include any adjustments to the amounts and classification
of assets and liabilities that might be necessary should the Company not be able to continue as a going concern.
| |
d. |
The
Company has two wholly-owned U.S. subsidiaries: (i) BriaCell Therapeutics Corp. (“BTC”),
which was incorporated in April 3, 2014, under the laws of the state of Delaware, and (ii)
BTC has a wholly-owned subsidiary, Sapientia Pharmaceuticals, Inc. (“Sapientia”),
which was incorporated in September 20, 2012, under the laws of the state of Delaware. The
Company also has one Canadian subsidiary: BriaPro Therapeutics Corp, (“BriaPro”)
which was incorporated on May 15, 2023, under the Business Corporations Act (British Columbia).
BriaPro was established to complete a plan of arrangement spinout transaction in August 2023,
pursuant to which certain pipeline assets of the Company were spun-out to BriaPro, including
Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications
including cancer (the “BriaPro Assets”), resulting in a two-third (2/3) owned
subsidiary of the Company with the remaining one-third (1/3) held by the Company’s
shareholders (the “Amalgamation” and the “Amalgamation Agreement”) – see also note 7(a). (Sapientia and BTC and BriaPro together, the “Subsidiaries”) |
| |
|
|
| |
e. |
The
Company has one operating segment and reporting unit. |
BriaCell
Therapeutics Corp
Notes
to the Consolidated Financial Statements
For
the Years Ended July 31, 2025 and 2024
(Expressed
in US Dollars, except share and per share data and unless otherwise indicated)
|